. advertisement .china's plans to import indian drugs fail to enthuse indian pharmaceutical firms . .hide comments . . cambridge's bluebird bio licenses delivery tech to novartis, gsk .-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018. .: "fremanezumab for the preventive treatment of chronic migraine."